Kenvue Inc. $KVUE Shares Sold by Mizuho Markets Americas LLC

Mizuho Markets Americas LLC decreased its stake in Kenvue Inc. (NYSE:KVUE) by 85.0% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 2,123,921 shares of the company’s stock after selling 12,030,014 shares during the quarter. Kenvue comprises approximately 1.0% of Mizuho Markets Americas LLC’s portfolio, making the stock its 28th largest position. Mizuho Markets Americas LLC’s holdings in Kenvue were worth $36,616,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Elyxium Wealth LLC acquired a new position in Kenvue during the 4th quarter worth approximately $26,000. Physician Wealth Advisors Inc. boosted its holdings in Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after acquiring an additional 618 shares during the period. MV Capital Management Inc. acquired a new stake in Kenvue in the fourth quarter valued at approximately $28,000. Reflection Asset Management acquired a new stake in Kenvue in the fourth quarter valued at approximately $32,000. Finally, SBI Securities Co. Ltd. raised its stake in shares of Kenvue by 82.4% during the fourth quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock valued at $39,000 after purchasing an additional 1,027 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Down 1.2%

NYSE:KVUE opened at $18.89 on Friday. The company has a market capitalization of $36.28 billion, a price-to-earnings ratio of 22.23, a price-to-earnings-growth ratio of 1.45 and a beta of 0.47. Kenvue Inc. has a one year low of $14.02 and a one year high of $22.87. The stock has a 50-day simple moving average of $18.33 and a 200 day simple moving average of $17.91. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.05. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The firm had revenue of $3.91 billion for the quarter, compared to analysts’ expectations of $3.84 billion. During the same quarter in the prior year, the firm posted $0.24 earnings per share. Kenvue’s revenue for the quarter was up 4.5% compared to the same quarter last year. Sell-side analysts predict that Kenvue Inc. will post 1.16 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th were issued a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.4%. The ex-dividend date was Wednesday, May 13th. Kenvue’s payout ratio is 97.65%.

Insider Buying and Selling at Kenvue

In related news, General Counsel Matthew Orlando sold 38,491 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 1.59% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on KVUE. Barclays boosted their target price on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research report on Tuesday. Citigroup dropped their price target on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 15th. Weiss Ratings raised shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. Wall Street Zen upgraded shares of Kenvue to a “buy” rating in a report on Sunday, July 12th. Finally, Zacks Research cut shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Three research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. According to MarketBeat, Kenvue has a consensus rating of “Hold” and an average target price of $19.58.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.